> **来源：[研报客](https://pc.yanbaoke.cn)** # Summary of "Charting Digital Disruption in the Life Sciences Sector" ## Core Content This whitepaper provides an analysis of the adoption and impact of digital technologies in the life sciences sector, based on a 2024 survey of 101 professionals from pharmaceutical, biopharmaceutical, and biotechnology companies. It builds on a 2019 survey and explores how the industry has evolved in its approach to digital transformation, highlighting both progress and ongoing challenges. ## Main Views and Key Information ### **Digital Transformation in Drug Development** - **Rising Adoption of AI and Big Data**: 49% of respondents in 2024 reported that their organisation was actively using AI and big data analytics in development programs, up from 39% in 2019. The number of organisations piloting these technologies also increased from 29% to 35%. - **Systemic Integration Challenges**: Despite increased usage, only 13% of organisations have a comprehensive program for integrating AI and big data into development projects, showing that systemic adoption is still limited. - **Shift in Perception**: The proportion of respondents who believed digital technologies would have no effect on operations dropped from 29% in 2019 to 11% in 2024, indicating growing recognition of their value. ### **Value Propositions of Digital Tools** - **High Impact Areas**: Respondents identified predictive tools, biomarker discovery, and safety and efficacy signal detection as the most promising areas for digital technologies in R&D, with 46%, 44%, and 43% respectively indicating "great value." - **Other High Potential Areas**: These include preclinical research, refining dosing and protocols based on real-world evidence, patient recruitment, rapid diagnosis, and improved communication with customers. - **Consistent Ratings**: The perceived value of digital tools across different R&D areas has remained relatively stable since 2019, suggesting a mature understanding of their potential. ### **Drivers for Adoption** - **Improving ROI**: 82% of respondents believe digital tools will improve return on R&D investments. - **Enhancing Product Safety and Efficacy**: 76% of respondents believe digital tools will enhance product safety and efficacy. - **Competing in Targeted Markets**: 76% of respondents believe digital technologies will help organisations compete in targeted medicine markets, which has moved up in importance over the past five years. ### **Barriers to Adoption** - **Decreasing Perceived Barriers**: On average, the significance of barriers to digital adoption has decreased since 2019, with 58% of respondents now identifying a lack of regulatory support as the most significant current barrier. - **Regulatory Constraints**: The European Union's AI Act is cited as a recent event that may have increased the perception of regulatory challenges. ### **Investment Trends** - **Increased Spending**: 88% of respondents expect their organisation to increase investment in digital-enabled technologies over the next one to two years, with an estimated 34% average increase and 27% of organisations planning to increase spending by over 41%. - **Partnership Strategies**: While internal development remains a key strategy, there is a growing preference for partnerships with technology consultants and companies over CROs, reflecting a shift in how organisations are approaching digital maturity. ### **Strategies for Future Success** - **Strategic Investment**: Organisations must focus on areas where digital tools can deliver measurable value, such as predictive modelling, biomarker discovery, and patient recruitment. - **Leverage Partnerships**: Strategic collaborations with technology vendors, CROs, and consultants can accelerate digital integration and improve competitive positioning. - **Regulatory Engagement**: Proactive engagement with regulatory bodies is essential to overcome barriers and ensure the development of supportive frameworks. - **Organisational Readiness**: Building a culture of digital literacy and innovation through training, cross-functional collaboration, and leadership alignment is crucial for a successful digital transformation. ## Conclusion The life sciences sector is undergoing significant digital disruption, with a growing recognition of the value of AI, machine learning, and big data analytics in drug development. While adoption is increasing, systemic integration remains a challenge. The report serves as a roadmap for biopharma leaders to make informed decisions that drive innovation, enhance R&D productivity, and ultimately improve patient outcomes. The future of drug development is being redefined, and organisations that act decisively will lead the way. ## Further Reading - **Whitepaper**: "Digital Disruption in Biopharma" and "Advancements in Artificial Intelligence for Site Selection" - **Blog**: "The Rise and Role of AI in Medical Imaging" - **Weblink**: "AI and Clinical Trials Insights" for the latest thought leadership from ICON.